The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: A tripartite pathophysiological circuit with implications for new therapeutic directions

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 4, 2016, Pages 606-625

  Vindigni, Stephen M ^a   Zisman, Timothy L ^a   Suskind, David L ^b   Damman, Christopher J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

barrier function; Crohn's disease; inflammatory bowel disease; leaky gut; microbiome

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOMODULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; TETRACYCLINE;

ACNE; APPENDECTOMY; COLON RESECTION; CROHN DISEASE; DIET THERAPY; DISEASE EXACERBATION; DYSBIOSIS; ENVIRONMENTAL FACTOR; FECAL MICROBIOTA TRANSPLANTATION; GENETIC RISK; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; HYGIENE; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE FUNCTION; INTESTINE MUCOSA; MICROBIAL ACTIVITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SPECIES COMPOSITION; STRESS; TOBACCO USE; ULCERATIVE COLITIS;

EID: 84975063130     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16644242     Document Type: Review

References (245)

1. Aamann L., Vestergaard E., Gronbaek H., (2014) Trefoil factors in inflammatory bowel disease. World J Gastroenterol 20: 3223-3230.
2. Abraham C., Medzhitov R., (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140: 1729-1737.
3. Achilles S., Hillier S., (2013) The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS 27 (Suppl. 1): S5-S15.
4. Akobeng A., Miller V., Stanton J., Elbadri A., Thomas A., (2000) Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 30: 78-84.
5. Alic M., (2000) Epidemiology supports oral contraceptives as a risk factor in Crohn's disease. Gut 46: 140.
6. Alikhan A., Henderson G., Becker L., Sciallis G., (2011) Acne treatment and inflammatory bowel disease: what is the evidence? J Am Acad Dermatol 65: 650-654.
7. Ananthakrishnan A., (2013) Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) 9: 367-374.
8. Ananthakrishnan A., Higuchi L., Huang E., Khalili H., Richter J., Fuchs C., et al. (2012) Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 156: 350-359.
9. Andersson R., Olaison G., Tysk C., Ekbom A., (2003) Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 124: 40-46.
10. Andrews C., Griffiths T., Kaufman J., Vergnolle N., Surette M., Rioux K., (2011) Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 34: 374-383.
11. Angelberger S., Reinisch W., Makristathis A., Lichtenberger C., Dejaco C., Papay P., et al. (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108: 1620-1630.
12. Antharam V., Li E., Ishmael A., Sharma A., Mai V., Rand K., et al. (2013) Intestinal dysbiosis and depletion of butyrogenic bacteria in clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 51: 2884-2892.
13. Arnold G., Beaves M., Pryjdun V., Mook W., (2002) Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 8: 10-15.
14. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D., et al. (2011) Enterotypes of the human gut microbiome. Nature 473: 174-180.
15. Atarashi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y., et al. (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331: 337-341.
16. Bager P., Simonsen J., Nielsen N., Frisch M., (2012) Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis 18: 857-862.
17. Bangsgaard Bendtsen K., Krych L., Sorensen D., Pang W., Nielsen D., Josefsen K., et al. (2012) Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PLoS One 7: e46231.
18. Barclay A., Russell R., Wilson M., Gilmour W., Satsangi J., Wilson D., (2009) Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 155: 421-426.
19. Bejaoui M., Sokol H., Marteau P., (2015) Targeting the microbiome in inflammatory bowel disease: critical evaluation of current concepts and moving to new horizons. Dig Dis 33 (Suppl. 1): 105-112.
20. Bellaguarda E., Chang E., (2015) IBD and the gut microbiota-from bench to personalized medicine. Curr Gastroenterol Rep 17: 15.
21. Benjamin J., Hedin C., Koutsoumpas A., Ng S., McCarthy N., Prescott N., et al. (2012) Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 18: 1092-1100.
22. Berg A., Kelly C., Farraye F., (2013) Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis 19: 194-204.
23. Bernstein C., Shanahan F., (2008) Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57: 1185-1191.
24. Bertrand J., Ghouzali I., Guerin C., Bole-Feysot C., Gouteux M., Dechelotte P., et al. (2015) Glutamine restores tight junction protein claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome. JPEN J Parenter Enteral Nutr, 13 May 2015 [Epub ahead of print].
25. Bianco A., Girardelli M., Tommasini A., (2015) Genetics of inflammatory bowel disease from multifactorial to monogenic forms. World J Gastroenterol 21: 12296-12310.
26. Biedermann L., Zeitz J., Mwinyi J., Sutter-Minder E., Rehman A., Ott S., et al. (2013) Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One 8: e59260.
27. Blonski W., Buchner A., Aberra F., Lichtenstein G., (2013) Teduglutide in Crohn's disease. Expert Opin Biol Ther 13: 1207-1214.
28. Bollhalder L., Pfeil A., Tomonaga Y., Schwenkglenks M., (2013) A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clin Nutr 32: 213-223.
29. Borody T., Paramsothy S., Agrawal G., (2013) Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 15: 337.
30. Borrelli O., Cordischi L., Cirulli M., Paganelli M., Labalestra V., Uccini S., et al. (2006) Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 4: 744-753.
31. Bourlioux P,. and Workgroup of the French Academy of Pharmacy (2015) Faecal microbiota transplantation: key points to consider. Ann Pharm Fr 73: 163-168.
32. Brandt L., Bernstein L., Boley S., Frank M., (1982) Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 83: 383-387.
33. Buchman A., Katz S., Fang J., Bernstein C., Abou-Assi S., Teduglutide Study Group (2010) Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 16: 962-973.
34. Buhner S., Buning C., Genschel J., Kling K., Herrmann D., Dignass A., et al. (2006) Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 55: 342-347.
35. Busquets D., Mas-De-Xaxars T., Lopez-Siles M., Martinez-Medina M., Bahi A., Sabat M., et al. (2015) Anti-tumour necrosis factor treatment with adalimumab induces changes in the microbiota of Crohn's disease. J Crohns Colitis 9: 899-906.
36. Camilleri M., Madsen K., Spiller R., Greenwood-Van Meerveld B., Verne G., (2012) Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 24: 503-512.
37. Cammarota G., Ianiro G., Cianci R., Bibbò S., Gasbarrini A., Currò D., (2015) The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 149: 191-212.
38. Cani P., Possemiers S., Van De, Wiele T., Guiot Y., Everard A., Rottier O., et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091-1103.
39. Catanzaro D., Rancan S., Orso G., Dall'acqua S., Brun P., Giron M., et al. (2015) Boswellia serrata preserves intestinal epithelial barrier from oxidative and inflammatory damage. PLoS One 10: e0125375.
40. Chan S., Luben R., Bergmann M., Boeing H., Olsen A., Tjonneland A., et al. (2011) Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther 34: 649-655.
41. Chapman-Kiddell C., Davies P., Gillen L., Radford-Smith G., (2010) Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis 16: 137-151.
42. Chassaing B., Koren O., Goodrich J., Poole A., Srinivasan S., Ley R., et al. (2015) Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519: 92-96.
43. Cheluvappa R., Luo A.S., Grimm M.C., (2014) Autophagy Suppression by Appendicitis and Appendectomy Protects against Colitis. Inflamm Bowel Dis 20: 847-855.
44. Chiba M., Abe T., Tsuda H., Sugawara T., Tsuda S., Tozawa H., et al. (2010) Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. World J Gastroenterol 16: 2484-2495.
45. Chow J., Tang H., Mazmanian S., (2011) Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol 23: 473-480.
46. Clayton E., Rea M., Shanahan F., Quigley E., Kiely B., Hill C., et al. (2009) The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 104: 1162-1169.
47. Cohen S., Gold B., Oliva S., Lewis J., Stallworth A., Koch B., et al. (2014) Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 59: 516-521.
48. Collins S., Surette M., Bercik P., (2012) The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 10: 735-742.
49. Colman R., Rubin D., (2014) Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 8: 1569-1581.
50. Cosnes J., (2008) What is the link between the use of tobacco and IBD? Inflamm Bowel Dis 14 (Suppl. 2): S14-S15.
51. Cosnes J., Carbonnel F., Carrat F., Beaugerie L., Gendre J., (1999) Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut 45: 218-222.
52. Critch J., Day A., Otley A., King-Moore C., Teitelbaum J., Shashidhar H., et al. (2012) Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 54: 298-305.
53. Cui B., Feng Q., Wang H., Wang M., Peng Z., Li P., et al. (2015) Fecal microbiota transplantation through mid-gut for refractory crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 30: 51-58.
54. Dalal S., Chang E., (2014) The microbial basis of inflammatory bowel diseases. J Clin Invest 124: 4190-4196.
55. Damman C., (2013) Salicylates and the microbiota: a new mechanistic understanding of an ancient drug's role in dermatological and gastrointestinal disease. Drug Development Research 74: 344-352.
56. Damman C., Brittnacher M., Westerhoff M., Hayden H., Radey M., Hager K., et al. (2015) Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. PLoS One 10: e0133925.
57. Damman C., Miller S., Surawicz C., Zisman T., (2012) The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 107: 1452-1459.
58. Darfeuille-Michaud A., Boudeau J., Bulois P., Neut C., Glasser A., Barnich N., et al. (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127: 412-421.
59. David L., Maurice C., Carmody R., Gootenberg D., Button J., Wolfe B., et al. (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505: 559-563.
60. D'Inca R., Annese V., Di Leo V., Latiano A., Quaino V., Abazia C., et al. (2006) Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther 23: 1455-1461.
61. Deplancke B., Gaskins H., (2001) Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr 73: 1131S-1141S.
62. Derrien M., Vaughan E., Plugge C., De Vos W., (2004) Akkermansia muciniphila gen. Nov., sp. Nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54: 1469-1476.
63. Devkota S., Wang Y., Musch M., Leone V., Fehlner-Peach H., Nadimpalli A., et al. (2012) Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10-/- mice. Nature 487: 104-108.
64. Di Bella S., Gouliouris T., Petrosillo N,. (2015) Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother 21: 230-237.
65. Dominguez-Bello M., Costello E., Contreras M., Magris M., Hidalgo G., Fierer N., et al. (2010) Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 107: 11971-11975.
66. Dupont H., (2014) Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 39: 1033-1042.
67. Eckburg P., Bik E., Bernstein C., Purdom E., Dethlefsen L., Sargent M., et al. (2005) Diversity of the human intestinal microbial flora. Science 308: 1635-1638.
68. Edelblum K., Turner J., (2009) The tight junction in inflammatory disease: communication breakdown. Curr Opin Pharmacol 9: 715-720.
69. Faith J., Rey F., O'Donnell D., Karlsson M., McNulty N., Kallstrom G., et al. (2010) Creating and characterizing communities of human gut microbes in gnotobiotic mice. ISME J 4: 1094-1098.
70. Fallani M., Young D., Scott J., Norin E., Amarri S., Adam R., et al. (2010) Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. J Pediatr Gastroenterol Nutr 51: 77-84.
71. Feldman M., Friedman L., Brandt L., (2015) Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Saunders.
72. Fernandes P., Macsharry J., Darby T., Fanning A., Shanahan F., Houston A., et al. (2015) Differential expression of key regulators of toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and PPARgamma? Clin Exp Immunol 183: 358-368.
73. Frank D., St Amand A., Feldman R., Boedeker E., Harpaz N., Pace N., (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104: 13780-13785.
74. Freedberg D., Toussaint N., Chen S., Ratner A., Whittier S., Wang T., et al. (2015) Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149: 883-885 e889.
75. Fujimoto T., Imaeda H., Takahashi K., Kasumi E., Bamba S., Fujiyama Y., et al. (2013) Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol 28: 613-619.
76. Gearry R., Irving P., Barrett J., Nathan D., Shepherd S., Gibson P., (2009) Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis 3: 8-14.
77. Gerasimidis K., Bertz M., Hanske L., Junick J., Biskou O., Aguilera M., et al. (2014) Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition. Inflamm Bowel Dis 20: 861-871.
78. Geremia A., Biancheri P., Allan P., Corazza G., Di Sabatino A., (2014) Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13: 3-10.
79. Gevers D., Kugathasan S., Denson L., Vazquez-Baeza Y., Van Treuren W., Ren B., et al. (2014) The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15: 382-392.
80. Gilardi D., Fiorino G., Genua M., Allocca M., Danese S., (2014) Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? Expert Rev Gastroenterol Hepatol 8: 835-846.
81. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309.
82. Gorard D., Hunt J., Payne-James J., Palmer K., Rees R., Clark M., et al. (1993) Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 34: 1198-1202.
83. Gough E., Shaikh H., Manges A., (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53: 994-1002.
84. Guaraldi F., Salvatori G., (2012) Effect of breast and formula feeding on gut microbiota shaping in newborns. Front Cell Infect Microbiol 2: 94.
85. Guinane C., Tadrous A., Fouhy F., Ryan C., Dempsey E., Murphy B., et al. (2013) Microbial composition of human appendices from patients following appendectomy. MBio 4: e00366-12.
86. Guslandi M., (2011) Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 17: 4643-4646.
87. Hajishengallis G., Darveau R., Curtis M., (2012) The Keystone-Pathogen hypothesis. Nat Rev Microbiol 10: 717-725.
88. Halfvarson J., (2011) Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis 17: 6-12.
89. Halme L., Paavola-Sakki P., Turunen U., Lappalainen M., Farkkila M., Kontula K., (2006) Family and twin studies in inflammatory bowel disease. World J Gastroenterol 12: 3668-3672.
90. Hamady M., Knight R., (2009) Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res 19: 1141-1152.
91. Hansen J., Sartor R., (2015) Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol 13: 105-120.
92. Hedin C., McCarthy N., Louis P., Farquharson F., McCartney S., Taylor K., et al. (2014) Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 63: 1578-1586.
93. Henker J., Müller S., Laass M., Schreiner A., Schulze J., (2008) Probiotic Escherichia coli Nissle 1917 (ECN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 46: 874-875.
94. Heyland D., Muscedere J., Wischmeyer P., Cook D., Jones G., Albert M., et al. (2013) A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 368: 1489-1497.
95. Hooper L., Macpherson A., (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10: 159-169.
96. Hou J., Abraham B., El-Serag H., (2011) Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 106: 563-573.
97. Human Microbiome Project Consortium (2012) Structure, function and diversity of the healthy human microbiome. Nature 486: 207-214.
98. Ianiro G., Bruno G., Lopetuso L., Beghella F., Laterza L., D'Aversa F., et al. (2014) Role of yeasts in healthy and impaired gut microbiota: the gut mycome. Curr Pharm Des 20: 4565-4569.
99. Iliev I., Funari V., Taylor K., Nguyen Q., Reyes C., Strom S., et al. (2012) Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science 336: 1314-1317.
100. Integrative HMP (iHMP) Research Network Consortium (2014) The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16: 276-289.
101. Jeffery I., Claesson M., O'Toole P., Shanahan F., (2012) Categorization of the gut microbiota: enterotypes or gradients? Nat Rev Microbiol 10: 591-592.
102. Jeppesen P., (2012) Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol 5: 159-171.
103. Johansson M., Gustafsson J., Holmen-Larsson J., Jabbar K., Xia L., Xu H., et al. (2014) Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63: 281-291.
104. Johansson M., Phillipson M., Petersson J., Velcich A., Holm L., Hansson G., (2008) The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105: 15064-15069.
105. Jostins L., Ripke S., Weersma R., Duerr R., McGovern D., Hui K., et al. (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119-124.
106. Kakodkar S., Farooqui A., Mikolaitis S., Mutlu E., (2015) The specific carbohydrate diet for inflammatory bowel disease: a case series. J Acad Nutr Diet 115: 1226-1232.
107. Kamada N., Chen G., Inohara N., Nunez G., (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14: 685-690.
108. Kaplan G., Jackson T., Sands B., Frisch M., Andersson R., Korzenik J., (2008) The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol 103: 2925-2931.
109. Kaplan G., Pedersen B., Andersson R., Sands B., Korzenik J., Frisch M., (2007) The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut 56: 1387-1392.
110. Karner M., Kocjan A., Stein J., Schreiber S., Von Boyen G., Uebel P., et al. (2014) First multicenter study of modified release phosphatidylcholine 'LT-02' in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 109: 1041-1051.
111. Kato L., Kawamoto S., Maruya M., Fagarasan S., (2014) The role of the adaptive immune system in regulation of gut microbiota. Immunol Rev 260: 67-75.
112. Kelly C., Ihunnah C., Fischer M., Khoruts A., Surawicz C., Afzali A., et al. (2014) Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109: 1065-1071.
113. Khan K., Ullman T., Ford A., Abreu M., Abadir A., Marshall J., et al. (2011) Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106: 661-673.
114. Klapproth J., Sasaki M., (2010) Bacterial induction of proinflammatory cytokines in inflammatory bowel disease. Inflamm Bowel Dis 16: 2173-2179.
115. Knights D., Lassen K., Xavier R., (2013) Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 62: 1505-1510.
116. Koenig J., Spor A., Scalfone N., Fricker A., Stombaugh J., Knight R., et al. (2011) Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 108 (Suppl. 1): 4578-4585.
117. Koloski N., Bret L., Radford-Smith G., (2008) Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol 14: 165-173.
118. Kostic A., Xavier R., Gevers D., (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146: 1489-1499.
119. Kronman M., Zaoutis T., Haynes K., Feng R., Coffin S., (2012) Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 130: e794-e803.
120. Kruis W., Fric P., Pokrotnieks J., Lukás M., Fixa B., Kascák M., et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623.
121. Kump P., Gröchenig H., Lackner S., Trajanoski S., Reicht G., Hoffmann K., et al. (2013) Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19: 2155-2165.
122. Kunde S., Pham A., Bonczyk S., Crumb T., Duba M., Conrad H. Jr, et al. (2013) Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56: 597-601.
123. Lee D., Albenberg L., Compher C., Baldassano R., Piccoli D., Lewis J., et al. (2015) Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology 148: 1087-1106.
124. Lepage P., Leclerc M., Joossens M., Mondot S., Blottiere H., Raes J., et al. (2013) A metagenomic insight into our gut's microbiome. Gut 62: 146-158.
125. Lerner A., Matthias T., (2015) Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev 14: 479-489.
126. Ley R., Peterson D., Gordon J., (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124: 837-848.
127. Li Q., Zhang Q., Wang M., Zhao S., Ma J., Luo N., et al. (2008) Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. Clin Immunol 126: 67-80.
128. Louis P., Hold G., Flint H., (2014) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12: 661-672.
129. Lozupone C., Stombaugh J., Gordon J., Jansson J., Knight R., (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489: 220-230.
130. Lutgendorff F., Akkermans L., Soderholm J., (2008) The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med 8: 282-298.
131. Maccaferri S., Vitali B., Klinder A., Kolida S., Ndagijimana M., Laghi L., et al. (2010) Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 65: 2556-2565.
132. MacDermott R., Nash G., Nahm M., (1989) Antibody secretion by human intestinal mononuclear cells from normal controls and inflammatory bowel disease patients. Immunol Invest 18: 449-457.
133. Machiels K., Joossens M., Sabino J., De Preter V., Arijs I., Eeckhaut V., et al. (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63: 1275-1283.
134. Man S., Kaakoush N., Mitchell H., (2011) The role of bacteria and pattern-recognition receptors in Crohn's disease. Nat Reva Gastroenterol Hepatol 8: 152-168.
135. Manichanh C., Borruel N., Casellas F., Guarner F., (2012) The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9: 599-608.
136. Manichanh C., Rigottier-Gois L., Bonnaud E., Gloux K., Pelletier E., Frangeul L., et al. (2006) Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55: 205-211.
137. Margolis D., Fanelli M., Hoffstad O., Lewis J., (2010) Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 105: 2610-2616.
138. Martinez-Medina M., Denizot J., Dreux N., Robin F., Billard E., Bonnet R., et al. (2014) Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 63: 116-124.
139. Matsunaga H., Hokari R., Ueda T., Kurihara C., Hozumi H., Higashiyama M., et al. (2011) Physiological stress exacerbates murine colitis by enhancing proinflammatory cytokine expression that is dependent on IL-18. Am J Physiol Gastrointest Liver Physiol 301: G555-G564.
140. McGilligan V., Wallace J., Heavey P., Ridley D., Rowland I., (2007) The effect of nicotine in vitro on the integrity of tight junctions in Caco-2 cell monolayers. Food Chem Toxicol 45: 1593-1598.
141. McGovern D., Kugathasan S., Cho J., (2015) Genetics of inflammatory bowel diseases. Gastroenterology 149: 1163-1176.e1162.
142. McNees A.L., Markesich D., Zayyani N.R., Graham D.Y., (2015) Mycobacterium paratuberculosis as a cause of Crohn's disease. Expert Rev Gastroenterol Hepatol 9: 1523-1534.
143. Melgar S., Engstrom K., Jagervall A., Martinez V., (2008) Psychological stress reactivates dextran sulfate sodium-induced chronic colitis in mice. Stress 11: 348-362.
144. Merga Y., Campbell B., Rhodes J., (2014) Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy. Dig Dis 32: 475-483.
145. Metzker M., (2010) Sequencing technologies-the next generation. Nat Rev Genet 11: 31-46.
146. Michail S., Durbin M., Turner D., Griffiths A., Mack D., Hyams J., et al. (2012) Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 18: 1799-1808.
147. Michielan A., D'Inca R., (2015) Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm 2015: 628157.
148. Miele E., Pascarella F., Giannetti E., Quaglietta L., Baldassano R., Staiano A., (2009) Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104: 437-443.
149. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I., et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108-114.
150. Moayyedi P., Surette M., Kim P., Libertucci J., Wolfe M., Onischi C., et al. (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149: 102-109 e106.
151. Modi S., Collins J., Relman D., (2014) Antibiotics and the gut microbiota. J Clin Invest 124: 4212-4218.
152. Moehle C., Ackermann N., Langmann T., Aslanidis C., Kel A., Kel-Margoulis O., et al. (2006) Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl) 84: 1055-1066.
153. Molodecky N., Soon I., Rabi D., Ghali W., Ferris M., Chernoff G., et al. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142: 46-54.e42; quiz e30.
154. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., et al. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571-607.
155. Nagalingam N., Lynch S., (2012) Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 18: 968-984.
156. Naganuma M., Iizuka B., Torii A., Ogihara T., Kawamura Y., Ichinose M., et al. (2001) Appendectomy protects against the development of ulcerative colitis and reduces its recurrence: results of a multicenter case-controlled study in Japan. Am J Gastroenterol 96: 1123-1126.
157. Nicholson J., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., et al. (2012) Host-gut microbiota metabolic interactions. Science 336: 1262-1267.
158. Nickerson K., Chanin R., McDonald C., (2015) Deregulation of intestinal anti-microbial defense by the dietary additive, maltodextrin. Gut Microbes 6: 78-83.
159. Norman J., Handley S., Baldridge M., Droit L., Liu C., Keller B., et al. (2015) Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160: 447-460.
160. Obih C., Wahbeh G., Lee D., Braly K., Giefer M., Shaffer M., et al. (2016) Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition 32: 418-425.
161. Ockenga J., Borchert K., Stuber E., Lochs H., Manns M., Bischoff S., (2005) Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr 59: 1302-1309.
162. Ogura Y., Bonen D., Inohara N., Nicolae D., Chen F., Ramos R., et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606.
163. O'Hara A., Shanahan F., (2006) The gut flora as a forgotten organ. EMBO Rep 7: 688-693.
164. Ott S., Musfeldt M., Wenderoth D., Hampe J., Brant O., Fölsch U., et al. (2004) Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53: 685-693.
165. Parkes G., Whelan K., Lindsay J., (2014) Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis 8: 717-725.
166. Parkes M., (2012) Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis. Dig Dis 30: 330-333.
167. Pastor Rojo O., Lopez San Roman A., Albeniz Arbizu E., De La Hera Martinez A., Ripoll Sevillano E., Albillos Martinez A,. (2007) Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 13: 269-277.
168. Penders J., Thijs C., Vink C., Stelma F., Snijders B., Kummeling I., et al. (2006) Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 118: 511-521.
169. Peng J., Shen J., Ran Z., (2014) Novel agents in the future: therapy beyond anti-TNF agents in inflammatory bowel disease. J Dig Dis 15: 585-590.
170. Petrof E., Gloor G., Vanner S., Weese S., Carter D., Daigneault M., et al. (2013) Stool substitute transplant therapy for the eradication of clostridium difficile infection: 'repoopulating' the gut. Microbiome 1: 3.
171. Petrof E., Khoruts A., (2014) From stool transplants to next-generation microbiota therapeutics. Gastroenterology 146: 1573-1582.
172. Png C., Linden S., Gilshenan K., Zoetendal E., McSweeney C., Sly L., et al. (2010) Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105: 2420-2428.
173. Prantera C., Lochs H., Campieri M., Scribano M., Sturniolo G., Castiglione F., et al. (2006) Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 23: 1117-1125.
174. Quince C., Ijaz U.Z., Loman N., Eren A.M., Saulnier D., Russell J., et al. (2015) Extensive Modulation of the Fecal Metagenome in Children with Crohn's Disease During Exclusive Enteral Nutrition. Am J Gastroenterol 110: 1718-1729.
175. Radford-Smith G., (2008) What is the importance of appendectomy in the natural history of IBD? Inflamm Bowel Dis 14 (Suppl. 2): S72-S74.
176. Radford-Smith G., Edwards J., Purdie D., Pandeya N., Watson M., Martin N., et al. (2002) Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 51: 808-813.
177. Rajendran N., Kumar D., (2010) Role of diet in the management of inflammatory bowel disease. World J Gastroenterol 16: 1442-1448.
178. Rajilic-Stojanovic M., Shanahan F., Guarner F., De Vos W., (2013) Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 19: 481-488.
179. Rajilic-Stojanovic M., Smidt H., De Vos W., (2007) Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 9: 2125-2136.
180. Ramasundara M., Leach S., Lemberg D., Day A., (2009) Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 24: 202-208.
181. Ray K., (2015) IBD. Gut microbiota in IBD goes viral. Nat Rev Gastroenterol Hepatol 12: 122.
182. Reiberger T., Ferlitsch A., Payer B., Mandorfer M., Heinisch B., Hayden H., et al. (2013) Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 58: 911-921.
183. Richard M., Lamas B., Liguori G., Hoffmann T., Sokol H., (2015) Gut fungal microbiota: the yin and yang of inflammatory bowel disease. Inflamm Bowel Dis 21: 656-665.
184. Riordan A., Hunter J., Cowan R., Crampton J., Davidson A., Dickinson R., et al. (1993) Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 342: 1131-1134.
185. Roeselers G., Ponomarenko M., Lukovac S., Wortelboer H., (2013) Ex vivo systems to study host-microbiota interactions in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 27: 101-113.
186. Rogers M., Aronoff D., (2015) The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect
187. Rook G., (2012) Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol 42: 5-15.
188. Rossen N., Fuentes S., Van Der Spek M., Tijssen J., Hartman J., Duflou A., et al. (2015) Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149: 110-118 e114.
189. Rubin D., (2013) Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol 108: 1631-1633.
190. Rungoe C., Langholz E., Andersson M., Basit S., Nielsen N., Wohlfahrt J., et al. (2014) Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 63: 1607-1616.
191. Sartor R., (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577-594.
192. Scanlan P., Marchesi J., (2008) Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces. ISME J 2: 1183-1193.
193. Scarpellini E., Ianiro G., Attili F., Bassanelli C., De Santis A., Gasbarrini A., (2015) The human gut microbiota and virome: potential therapeutic implications. Dig Liver Dis 47: 1007-1012.
194. Schultsz C., Van Den Berg F., Ten Kate F., Tytgat G., Dankert J., (1999) The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 117: 1089-1097.
195. Sekelja M., Berget I., Naes T., Rudi K., (2011) Unveiling an abundant core microbiota in the human adult colon by a phylogroup-independent searching approach. ISME J 5: 519-531.
196. Sekirov I., Russell S., Antunes L., Finlay B., (2010) Gut microbiota in health and disease. Physiol Rev 90: 859-904.
197. Shanahan F., (2012) The gut microbiota-a clinical perspective on lessons learned. Nat Rev Gastroenterol Hepatol 9: 609-614.
198. Shaw S., Blanchard J., Bernstein C., (2010) Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 105: 2687-2692.
199. Shaw S., Blanchard J., Bernstein C., (2011) Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol 106: 2133-2142.
200. Sheehan D., Moran C., Shanahan F., (2015) The microbiota in inflammatory bowel disease. J Gastroenterol 50: 495-507.
201. Sigall-Boneh R., Pfeffer-Gik T., Segal I., Zangen T., Boaz M., Levine A., (2014) Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis 20: 1353-1360.
202. Singh S., Graff L., Bernstein C., (2009) Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 104: 1298-1313; quiz 1314.
203. Smith P., Howitt M., Panikov N., Michaud M., Gallini C., Bohlooly Y., et al. (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341: 569-573.
204. Soderholm J., Yates D., Gareau M., Yang P., Macqueen G., Perdue M., (2002) Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress. Am J Physiol Gastrointest Liver Physiol 283: G1257-G1263.
205. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermúdez-Humarán L., Gratadoux J., et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105: 16731-16736.
206. Sood A., Midha V., Makharia G., Ahuja V., Singal D., Goswami P., et al. (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: 1202-1209, 1209.e1201.
207. Spor A., Koren O., Ley R., (2011) Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9: 279-290.
208. Strauss J., Kaplan G., Beck P., Rioux K., Panaccione R., Devinney R., et al. (2011) Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 17: 1971-1978.
209. Stremmel W., Hanemann A., Braun A., Stoffels S., Karner M., Fazeli S., et al. (2010) Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis-a review of three clinical trials. Expert Opin Investig Drugs 19: 1623-1630.
210. Sun J., Chang E., (2014) Exploring gut microbes in human health and disease: pushing the envelope. Genes Dis 1: 132-139.
211. Suskind D., Brittnacher M., Wahbeh G., Shaffer M., Hayden H., Qin X., et al. (2015) Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 21: 556-563.
212. Suskind D., Wahbeh G., Gregory N., Vendettuoli H., Christie D., (2014) Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. J Pediatr Gastroenterol Nutr 58: 87-91.
213. Sutherland L., Singleton J., Sessions J., Hanauer S., Krawitt E., Rankin G., et al. (1991) Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32: 1071-1075.
214. Swidsinski A., Dorffel Y., Loening-Baucke V., Theissig F., Ruckert J., Ismail M., et al. (2011) Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut 60: 34-40.
215. Swidsinski A., Loening-Baucke V., Bengmark S., Lochs H., Dorffel Y., (2007) Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis 13: 51-56.
216. Swidsinski A., Weber J., Loening-Baucke V., Hale L., Lochs H., (2005) Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43: 3380-3389.
217. Takeuchi K., Smale S., Premchand P., Maiden L., Sherwood R., Thjodleifsson B., et al. (2006) Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4: 196-202.
218. Talley N., Abreu M., Achkar J., Bernstein C., Dubinsky M., Hanauer S., et al. (2011) An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 106 (Suppl. 1): S2-25; quiz S26.
219. Theodorakopoulou M., Perros E., Giamarellos-Bourboulis E., Dimopoulos G., (2013) Controversies in the management of the critically ill: the role of probiotics. Int J Antimicrob Agents 42 (Suppl.): S41-S44.
220. Theodoratou E., Campbell H., Ventham N., Kolarich D., Pucic-Bakovic M., Zoldos V., et al. (2014) The role of glycosylation in IBD. Nat Rev Gastroenterol Hepatol 11: 588-600.
221. Tilg H., Kaser A., (2004) Diet and relapsing ulcerative colitis: take off the meat? Gut 53: 1399-1401.
222. Timmer A., Sutherland L., Martin F., (1998) Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 114: 1143-1150.
223. Turnbaugh P., Hamady M., Yatsunenko T., Cantarel B., Duncan A., Ley R., et al. (2009) A core gut microbiome in obese and lean twins. Nature 457: 480-484.
224. Turner D., Levine A., Kolho K., Shaoul R., Ledder O., (2014) Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 8: 1464-1470.
225. Turner J., (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809.
226. Tursi A., Brandimarte G., Papa A., Giglio A., Elisei W., Giorgetti G., et al. (2010) Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105: 2218-2227.
227. Ulluwishewa D., Anderson R., McNabb W., Moughan P., Wells J., Roy N., (2011) Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 141: 769-776.
228. Ursell L., Metcalf J., Parfrey L., Knight R., (2012) Defining the human microbiome. Nutr Rev 70 (Suppl. 1): S38-S44.
229. Van Immerseel F., Ducatelle R., De Vos M., Boon N., Van De Wiele T., Verbeke K., et al. (2010) Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 59: 141-143.
230. Van Limbergen J., Radford-Smith G., Satsangi J,. (2014) Advances in IBD genetics. Nat Rev Gastroenterol Hepatol 11: 372-385.
231. Van Nimwegen F., Penders J., Stobberingh E., Postma D., Koppelman G., Kerkhof M., et al. (2011) Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol 128: 948-955 e941-943.
232. Van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E., De Vos W., et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368: 407-415.
233. Voitk A., Echave V., Feller J., Brown R., Gurd F., (1973) Experience with elemental diet in the treatment of inflammatory bowel disease. is this primary therapy? Arch Surg 107: 329-333.
234. Wahed M., Corser M., Goodhand J., Rampton D., (2010) Does psychological counseling alter the natural history of inflammatory bowel disease? Inflamm Bowel Dis 16: 664-669.
235. Walters, S., Quiros, A., Rolston, M., Grishina, I., Li, J., Fenton, A., et al. (2014) Analysis of gut microbiome and diet modification in patients with Crohn's disease. SOJ Microbiol Infect Dis 2: 1-13.
236. Wang M., Ahrne S., Jeppsson B., Molin G., (2005) Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. FEMS Microbiol Ecol 54: 219-231.
237. Wang N., Wang G., Hao J., Ma J., Wang Y., Jiang X., et al. (2012) Curcumin ameliorates hydrogen peroxide-induced epithelial barrier disruption by upregulating heme oxygenase-1 expression in human intestinal epithelial cells. Dig Dis Sci 57: 1792-1801.
238. Willing B., Dicksved J., Halfvarson J., Andersson A., Lucio M., Zheng Z., et al. (2010) A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139: 1844-1854.e1841.
239. Wischmeyer P., (2007) Glutamine: mode of action in critical illness. Crit Care Med 35: S541-544.
240. Wolff M., Broadhurst M., Loke P., (2012) Helminthic therapy: improving mucosal barrier function. Trends Parasitol 28: 187-194.
241. Wu G., Bushmanc F., Lewis J., (2013) Diet, the human gut microbiota, and IBD. Anaerobe 24: 117-120.
242. Wu G., Chen J., Hoffmann C., Bittinger K., Chen Y., Keilbaugh S., et al. (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334: 105-108.
243. Zhang F., Wang H., Wang M., Cui B., Fan Z., Ji G., (2013) Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World J Gastroenterol 19: 7213-7216.
244. Zhang Y., Li Y., (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20: 91-99.
245. Zoetendal E., Rajilic-Stojanovic M., De Vos W., (2008) High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57: 1605-1615.